Perrigo Company Reports 7.2% Decline in Q1 2026 Net Sales, Operating Loss of $372.3 Million

Perrigo Company plc reported a significant decline in its financial performance for the first quarter of 2026, with net sales totaling $969.2 million, down 7.2% from $1,043.9 million in the same period last year. The decrease was primarily attributed to lower consumption in both the U.S. and Europe, particularly due to a reduced incidence of seasonal cough and cold illnesses, which led to lower retailer inventory levels. Gross profit also fell to $325.5 million, down from $392.3 million, resulting in a gross profit margin of 33.6%, compared to 37.6% in the prior year. The company reported an operating loss of $372.3 million, a stark contrast to the operating income of $46.9 million recorded in the previous year, largely due to a $330.8 million goodwill impairment charge.

In terms of segment performance, the Self Care segment saw a notable decline in net sales, dropping 11.5% to $543.3 million, while the Specialty Care segment experienced a modest increase of 4.0% to $207.0 million. The Infant Formula segment reported a slight increase in sales to $89.7 million, but its operating income fell to a loss of $7.4 million, down from a profit of $10.6 million. The All Other category, which includes the Dermacosmetics business, saw sales decrease to $129.2 million, but operating income improved significantly to $31.9 million, driven by a recovery of previously paid tariffs.

Strategically, Perrigo has undergone significant organizational changes, transitioning from a geographic segment reporting structure to one based on product categories. This shift aims to better align financial disclosures and operational analysis with the company's strategic priorities. Additionally, the company completed the sale of its Dermacosmetics business for up to €332.6 million, which includes an upfront cash payment and potential earn-out payments based on future performance. This divestiture is part of Perrigo's broader strategy to streamline operations and focus on higher-margin product categories.

Operationally, Perrigo has faced challenges due to macroeconomic factors, including inflation and supply chain disruptions, which have impacted costs and production capabilities. The company has initiated several restructuring programs, including the Supply Chain Reinvention Program and Project Energize, aimed at reducing costs and improving operational efficiency. These initiatives are expected to yield significant savings, although they have also incurred substantial costs. As of March 28, 2026, Perrigo's cash and cash equivalents stood at $357.2 million, down from $531.6 million at the end of 2025, reflecting the company's ongoing investments and operational challenges.

Looking ahead, Perrigo's management remains cautious about the economic environment, including potential impacts from geopolitical tensions and inflationary pressures. The company is focused on stabilizing its core business while pursuing strategic initiatives to enhance shareholder value. The outlook for the remainder of 2026 will depend on the successful execution of these strategies and the ability to navigate the evolving market conditions.